Urinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary syndrome: A pilot study considering neglected steroid metabolites.

TitreUrinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary syndrome: A pilot study considering neglected steroid metabolites.
Publication TypeJournal Article
Year of Publication2018
AuthorsDhayat, NA, Marti, N, Kollmann, Z, Troendle, A, Bally, L, Escher, G, Grössl, M, Ackermann, D, Ponte, B, Pruijm, M, Müller, M, Vogt, B, Birkhäuser, MH, Bochud, M, Flück, CE
Corporate Authorsmembers of the SKIPOGH Study Group
JournalPLoS One
Volume13
Issue10
Paginatione0203903
Date Published10/2018
DOI10.1371/journal.pone.0203903
ISSN1932-6203
Mots-clésAdolescent, Adult, Case-Control Studies, Early Diagnosis, Female, Gas Chromatography-Mass Spectrometry, Humans, Metabolomics/methods, Middle Aged, Pilot Projects, Polycystic Ovary Syndrome/diagnosis, Polycystic Ovary Syndrome/metabolism, Polycystic Ovary Syndrome/urine, Prospective Studies, Sensitivity and Specificity, Steroids/urine, Young Adult
Abstract

BACKGROUND: Although the polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women with vast metabolic consequences, its etiology remains unknown and its diagnosis is still made by exclusion. This study aimed at characterizing a large number of urinary steroid hormone metabolites and enzyme activities in women with and without PCOS in order to test their value for diagnosing PCOS.

METHODS: Comparative steroid profiling of 24h urine collections using an established in-house gas-chromatography mass spectrometry method. Data were collected mostly prospectively. Patients were recruited in university hospitals in Switzerland. Participants were 41 women diagnosed with PCOS according to the current criteria of the Androgen Excess and PCOS Society Task Force and 66 healthy controls. Steroid profiles of women with PCOS were compared to healthy controls for absolute metabolite excretion and for substrate to product conversion ratios. The AUC for over 1.5 million combinations of metabolites was calculated in order to maximize the diagnostic accuracy in patients with PCOS. Sensitivity, specificity, PPV, and NPV were indicated for the best combinations containing 2, 3 or 4 steroid metabolites.

RESULTS: The best single discriminating steroid was androstanediol. The best combination to diagnose PCOS contained four of the forty measured metabolites, namely androstanediol, estriol, cortisol and 20βDHcortisone with AUC 0.961 (95% CI 0.926 to 0.995), sensitivity 90.2% (95% CI 76.9 to 97.3), specificity 90.8% (95% CI 81.0 to 96.5), PPV 86.0% (95% CI 72.1 to 94.7), and NPV 93.7% (95% CI 84.5 to 98.2).

CONCLUSION: PCOS shows a specific 24h urinary steroid profile, if neglected metabolites are included in the analysis and non-conventional data analysis applied. PCOS does not share a profile with hyperandrogenic forms of congenital adrenal hyperplasias due to single steroid enzyme deficiencies. Thus PCOS diagnosis by exclusion may no longer be warranted. Whether these findings also apply to spot urine and serum, remains to be tested as a next step towards routine clinical applicability.

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/30308019?dopt=Abstract

WOS ID (UT)

000447173500010

Alternate JournalPLoS ONE
Citation Key / SERVAL ID9134
Peer reviewRefereed
PubMed ID30308019

                         

IUMSP | www.iumsp.ch
Institut universitaire de médecine sociale et préventive
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | dess.info@unisante.ch

Go to top